Adult sensory neurons (purple) are protected from attack by activated macrophages (blue) when cultured with MultiStem (green). Credit: The University of Texas Health Science Center at Houston (UTHealth).

University of Texas Health Science Center at Houston (UTHealth) in the US has secured funding to conduct a Phase II trial of MultiStem for use in the early treatment and prevention of complications following severe traumatic injury.

The funding has been provided through a public/private partnership that includes Medical Technology Consortium (MTEC), Memorial Hermann Foundation and Athersys.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

MTEC’s funding makes up a sum of $2m, while Memorial Hermann Foundation has provided $1.5m. Athersys will provide its investigational stem cell therapy, MultiStem, in addition to regulatory and operational support for the trial.

"Our prior research demonstrates that administration of MultiStem following acute neurological injury can help improve recovery and reduce the occurrence or severity of certain complications."

The proposed double-blind, placebo-controlled trial expects to enrol around 150 severely injured trauma patients within hours of hospitalisation at Memorial Hermann-TMC, US.

Its design is yet to be reviewed by the US Food and Drug Administration (FDA) and receive approval from the UTHealth Internal Review Board, thereby making the design subject to change.

Once approved, UTHealth McGovern Medical School Neurosciences George and Cynthia Mitchell Distinguished Chair Charles Cox Jr will become the principal investigator of the trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cox Jr said: “Traumatic injury is the leading cause of death and disability among children and members of the military, and also has a significant impact on the elderly.

“Following serious trauma, an acute hyperinflammatory response can be triggered, impairing recovery and leading to additional complications.

“Our prior research demonstrates that administration of MultiStem following acute neurological injury can help improve recovery and reduce the occurrence or severity of certain complications, so we are excited about the clinical potential in this area.”

The MultiStem cell therapy is a patented regenerative medicine product that has demonstrated potential to help tissue repair and healing in various ways, including through the therapeutic factors produced in response to signals of inflammation and tissue damage.